At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
Multifocal D +2.50 add & 0.01% atropinecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Myopia Control in Children With Low-dose Atropine and Soft Bifocal Contact Lenses
In Brief
A clinical study evaluating Multifocal D +2.50 add & 0.01% atropine for Refractive Errors. Completed, enrolled 49 participants.
Detailed Summary
This study will test whether the combined treatment of 0.01% atropine and soft bifocal contact lens wear produces slower myopia progression and axial elongation compared to soft bifocal contact lenses alone in children ages 7 to 11 years old.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractive Errors
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedOct 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedOct 17, 2017
Enrollment StartJul 1, 2016
Primary CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.7 years ago
Interventions
Multifocal D +2.50 add & 0.01% atropinecombination
Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.